On May 9, 2023, Ben Tre Pharmaceutical Joint Stock Company (Bepharco, HOSE: DBT) successfully held the Annual General Meeting of Shareholders in fiscal year 2022.
Mr. Nguyen Khac Hanh – Chairman of the Board of Directors gave a welcome speech
Attending the Congress, on the side of the invited guests were:
- Mr. NGUYEN THANH TRUONG - Director of Vietinbank - Ben Tre Branch.
- Ms. HO THI MY LINH - Deputy in charge of customer department Vietinbank - Ben Tre Branch
- Mr. HO QUANG TIN - Head of Customer Service at Vietcombank - Phu Nhuan Branch
On behalf of the leadership of Ben Tre Pharmaceutical Joint Stock Company, we would like to introduce:
- Mr. Nguyen Khac Hanh - Chairman of the Board of Directors
- Mr. Pham Thu Trieu – Member of the Board of Directors
- Mr. Hoang Xuan An – Member of the Board of Directors
In 2022, the Company's production and business activities have achieved many proud results and exceeded the plan set out at the 2021 annual general meeting of shareholders. In which, the total consolidated revenue reached 754,618 billion VND and consolidated profit after tax reached 40.5 billion VND.
After the 2022 Performance Report, the Board of Directors and the Executive Board have set out the direction and business plan for 2023, in which:
- The consolidated revenue target is VND 1,105.0 billion VND, up 146% compared to 2022.
- Consolidated profit after tax is VND 42.2 billion VND, up 104% compared to 2022.
Accordingly, in 2023, Ben Tre Pharmaceutical Joint Stock Company will continue to consolidate the personnel system to complete positions, increase the connection of information from the market to the Board of Management to create a strong transformation. powerful and effective in decision making.
At the same time, promoting the search and development of potential products to put into business by attending CPHI in the world and major medical and pharmaceutical conferences; coordinate with universities, research institutes, scientific companies to receive scientific research topics on good and highly effective pharmaceutical products to serve the society...
Continuing to restructure assets that are not directly effective for the company's core business. Invest in a synchronous and effective way for the information technology system to serve management and business activities. Especially to meet the requirements of state management agencies and foreign partners.
On the same day, the General Meeting agreed on the dismissal of the position of member of the Board of Directors of the company with Mr. Tran Huy Chuong and agreed to additionally elect Mr. Nguyen Thanh Tung to the Board of Directors for the term 2019-2023.
The Annual General Meeting of Shareholders in fiscal year 2022 took place successfully. Strictly complying with the provisions of law, demonstrating the consensus and will of all shareholders to continue promoting innovation, ensuring the harmony of the interests of stakeholders in the development. sustainability of Bepharco.
Some pictures at the congress
